Hayley Pye
University College London
CytotoxicityCancerInternal medicineRadiologyPathologyMagnetic resonance imagingOncologyCytotoxic T cellAntibodyChemistryIn vitroImmunohistochemistryIn vivoEx vivoDysplasiaBiopsyProstateMUC1CarcinomaDiseaseProstate cancerSaporinPhotodynamic therapyOesophageal adenocarcinomaToxicityNuclear medicineCancer researchFlow cytometryEffective diffusion coefficientMedicineBiologyGastroenterology
45Publications
9H-index
171Citations
Publications 46
Newest
#1Marco Palombo (UCL: University College London)H-Index: 16
#2Valindria (UCL: University College London)
Last. Daniel C. Alexander (UCL: University College London)H-Index: 72
view all 11 authors...
Objectives. The Vascular, Extracellular, and Restricted Diffusion for Cytometry in Tumours (VERDICT) is a non-invasive MRI technique that has shown promising results in clinical settings discriminating normal from malignant tissue and Gleason grade 3+3 from 3+4. However, VERDICT currently does not account for the inherent relaxation properties of the tissue, whose quantification could provide additional information and enhance its diagnostic power. The aim of this work is to introduce relaxation...
Source
Source
#1Saurabh SinghH-Index: 5
Last. A. FreemanH-Index: 8
view all 16 authors...
Source
#1Benjamin S. Simpson (UCL: University College London)H-Index: 6
#2Hayley Pye (UCL: University College London)H-Index: 9
Last. Hayley C. Whitaker (UCL: University College London)H-Index: 24
view all 3 authors...
Recent developments in sequencing the cancer genome have provided the first in-depth mapping of structural variants (SV) across 38 tumour types. Sixteen signatures of structural variants have been proposed which broadly characterise the variation seen across cancer types. One signature shows increased duplications and deletions at fragile sites, with little association with the typical DNA repair defects. We discuss how, for many of these fragile sites, the clinical impacts are yet to be explore...
Source
#1Hayley PyeH-Index: 9
#2Saurabh SinghH-Index: 5
Last. Hayley C. WhitakerH-Index: 7
view all 37 authors...
Objectives: To assess the clinical outcomes of mpMRI before biopsy and evaluate the space remaining for novel biomarkers. Methods: The INNOVATE study was set up to evaluate the validity of novel fluidic biomarkers in men with suspected prostate cancer who undergo pre-biopsy mpMRI. We report the characteristics of this clinical cohort, the distribution of clinical serum biomarkers, PSA and PSA density (PSAD), and compare the mpMRI Likert scoring system to the Prostate Imaging–Reporting and Data S...
Source
#1Sabina Luszczak (UCL: University College London)H-Index: 1
#2Benjamin S. Simpson (UCL: University College London)H-Index: 6
Last. Susan Heavey (UCL: University College London)H-Index: 10
view all 19 authors...
Source
#1Lina M. Carmona Echeverria (UCL: University College London)H-Index: 4
#2Aiman Haider (UCLH: University College Hospital)H-Index: 6
Last. Hayley C. Whitaker (UCL: University College London)H-Index: 24
view all 32 authors...
Gleason score 7 prostate cancer with a higher proportion of pattern 4 (G4) has been linked to genomic heterogeneity and poorer patient outcome. The current assessment of G4 proportion uses estimation by a pathologist, with a higher proportion of G4 more likely to trigger additional imaging and treatment over active surveillance. This estimation method has been shown to have inter-observer variability. Fifteen patients with Prostate Grade Group (GG) 2 (Gleason 3 + 4) and fifteen patients with GG3...
1 CitationsSource
#1Benjamin S. Simpson (UCL: University College London)H-Index: 6
#2Niedzica Camacho (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 9
Last. Hayley C. Whitaker (UCL: University College London)H-Index: 2
view all 9 authors...
Source
#1Sabina Luszczak (UCL: University College London)H-Index: 1
#2Benjamin S. Simpson (UCL: University College London)H-Index: 6
Last. Susan Heavey (UCL: University College London)H-Index: 10
view all 19 authors...
PIM and PI3K/mTOR pathways are often dysregulated in prostate cancer, and may lead to decreased survival, increased metastasis and invasion. The pathways are heavily interconnected and act on a variety of common effectors that can lead to the development of resistance to drug inhibitors. Most current treatments exhibit issues with toxicity and resistance. We investigated the novel multikinase PIM/PI3K/mTOR inhibitor, AUM302, versus a combination of the PIM inhibitor, AZD-1208, and the PI3K/mTOR ...
1 CitationsSource
#1Benjamin S. Simpson (UCL: University College London)H-Index: 6
#2Niedzica Camacho (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 9
Last. Hayley C. Whitaker (UCL: University College London)H-Index: 2
view all 9 authors...
Large-scale genetic aberrations that underpin prostate cancer development and progression, such as copy-number alterations (CNAs), have been described but the consequences of specific changes in many identified loci is limited. Germline SNPs in the 3q26.31 locus are associated with aggressive prostate cancer, and is the location of NAALADL2, a gene overexpressed in aggressive disease. The closest gene to NAALADL2 is TBL1XR1, which is implicated in tumour development and progression. Using public...
1 CitationsSource